...
首页> 外文期刊>Biological & pharmaceutical bulletin >Paeonol Inhibits Oxidized Low Density Lipoprotein-Induced Monocyte Adhesion to Vascular Endothelial Cells by Inhibiting the Mitogen Activated Protein Kinase Pathway
【24h】

Paeonol Inhibits Oxidized Low Density Lipoprotein-Induced Monocyte Adhesion to Vascular Endothelial Cells by Inhibiting the Mitogen Activated Protein Kinase Pathway

机译:丹皮酚通过抑制丝裂原活化的蛋白激酶途径抑制氧化的低密度脂蛋白诱导的单核细胞粘附到血管内皮细胞。

获取原文
获取原文并翻译 | 示例

摘要

Atherosclerosis is a chronic inflammatory disease characterized by increased expression of adhesion molecules, which contribute to monocytes adhesion to vascular endothelial cells (VECs). Paeonol, an active compound isolated from cortex Montan, has been shown to have therapeutic effects on atherosclerotic ani-mals. The present study aims to investigate whether paeonol can inhibit monocyte adhesion to vascular en-dothelial cells induced by oxidized Low-Density Lipoprotein (ox-LDL) and its possible therapeutic molecular mechanism. Exposure to ox-LDL (50, 100μg/mL) induced damaged to VECs leading to decreased survival rates (p<0.01). Paeonol (7.2-18.0μM) partially restored survival and reduced lactate dehydrogenase (LDH) release in VECs in a concentration-dependent manner (p<0.01). Adhesion of monocytes to VECs was dra-matically prevented by paeonol at 21.6 and 25.2μm (p<0.01). In addition, paeonol (14.4-21.6μM) repressed the expression of vascular cell adhesion molecule-1 (VCAM-1) and lowered the levels of phosphor-c-Jun N-terminal kinase (P-JNK)1/2, phosphor-extracellular signal-regulated kinase (P-ERK)1/2 and P-p38 in a dose-dependent manner. The molecular effects of paeonol were more pronouced when companied with mitogen activated protein kinases (MAPKs) inhibitors. These data suggest that paeonol (10.8-25.2μm), at certain concentrations, prevents monocyte adhesion to VEC induced by ox-LDL., probably by means of blocking one or more target proteins on MAPKs signaling pathway. These results indicate that paeonol has potential pro-tective effects on the development of atherosclerosis.
机译:动脉粥样硬化是一种慢性炎性疾病,其特征在于粘附分子的表达增加,其促使单核细胞粘附于血管内皮细胞(VEC)。丹皮酚是一种从蒙塔皮层中分离的活性化合物,已显示出对动脉粥样硬化动物具有治疗作用。本研究旨在探讨丹皮酚是否能抑制单核细胞粘附于氧化型低密度脂蛋白(ox-LDL)诱导的血管内皮细胞及其可能的治疗分子机制。暴露于ox-LDL(50,100μg/ mL)会导致VEC受损,从而导致存活率降低(p <0.01)。丹皮酚(7.2-18.0μM)以浓度依赖的方式部分恢复了VEC中的存活并降低了乳酸脱氢酶(LDH)的释放(p <0.01)。丹皮酚在21.6和25.2μm时可显着防止单核细胞对VEC的粘附(p <0.01)。此外,丹皮酚(14.4-21.6μM)抑制血管细胞粘附分子1(VCAM-1)的表达,并降低磷-c-Jun N端激酶(P-JNK)1/2,磷-细胞外信号调节激酶(P-ERK)1/2和P-p38呈剂量依赖性。与有丝分裂原活化蛋白激酶(MAPKs)抑制剂同时使用时,丹皮酚的分子作用更为明显。这些数据表明,一定浓度的丹皮酚(10.8-25.2μm)可能是通过阻断MAPKs信号通路上的一种或多种靶蛋白来防止单核细胞粘附于ox-LDL诱导的VEC。这些结果表明丹皮酚对动脉粥样硬化的发展具有潜在的保护作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号